enGene (ENGN) Looks Coiled: A Technical Breakout Setup Ahead of Two 2026 Event Windows
enGene is a clinical-stage gene therapy company with a sharp recent re-rating and a chart pushing into fresh 52-week highs. With the stock still below its prior spike highs and short interest rising into year-end, this sets up as a mid-term catalyst trade into the back half of 2026. The plan is simple: buy strength near support, define risk below t…